This study provides a comprehensive framework for precision diagnosis and treatment of DSRCT through integrated multi-omics analysis, suggesting that low ERBB2 expression remains a viable biomarker for antibody-drug conjugate (ADC) therapy, with direct implications for clinical strategies in rare tumors.
Literature Overview
The article titled 'Multi-layered molecular profiling informs the diagnosis and targeted therapy of desmoplastic small round cell tumor,' published in Nature Communications, systematically investigates the multi-omics molecular characteristics of 30 patients with refractory DSRCT, revealing the critical role of molecular profiling in diagnostic refinement and personalized therapy. By integrating whole-genome/exome sequencing, transcriptome, methylome, and phosphoproteome data, the study demonstrates how multi-layered molecular analyses can enhance clinical management of rare tumors. The article further validates the durable efficacy of T-DXd treatment based on ERBB2 expression, even in the absence of kinase activation.Background Knowledge
DSRCT is an extremely rare and highly aggressive soft tissue sarcoma primarily affecting children and young males, with a 5-year survival rate below 15%. There is currently no standard systemic treatment, conventional chemotherapy has limited efficacy, and diagnosis is often delayed due to ambiguous histology. Although the specific EWSR1::WT1 fusion gene is present, no direct targeted drugs against this fusion protein are available, creating a therapeutic bottleneck. In recent years, despite breakthroughs in immunotherapy for various cancers, DSRCT is considered an 'immunologically cold' tumor and responds poorly to PD-1 inhibitors. Additionally, traditional targeted therapies often rely on empirical use of TKIs without biomarker guidance. Therefore, there is an urgent need for a systematic molecular atlas to identify druggable pathways. This study focuses on using multi-omics strategies to go beyond genomic mutations and uncover targetable abnormalities at the transcriptional and protein levels, particularly exploring the therapeutic potential of ERBB2 in the absence of kinase activation.
Research Methods and Experiments
The study included 30 patients with advanced DSRCT, all of whom underwent multi-layered molecular profiling as part of the German MASTER precision oncology program, including whole-genome/exome sequencing, RNA-seq, DNA methylation, proteome, and phosphoproteome analysis. Molecular Tumor Boards (MTB) provided treatment recommendations based on multi-omics data. To validate diagnostic accuracy, DNA methylation classifiers were used to reclassify samples. At the functional level, receptor tyrosine kinase (RTK) pathway activity—particularly the phosphorylation status of kinases such as ERBB2, KDR, and TYRO3—was assessed via phosphoproteomics to distinguish expression from activation. Treatment response was dynamically monitored using imaging and metabolic assessments (e.g., 18F-FDG-PET/CT), with PFSr (progression-free survival ratio before and after treatment) used to quantify efficacy.Key Conclusions and Perspectives
Research Significance and Prospects
This study provides a paradigm for precision medicine in rare tumors, emphasizing the necessity of integrated multi-omics approaches in diagnosis and treatment decision-making. Traditional mutation-dependent targeted strategies are limited in DSRCT, whereas abnormalities at the transcriptomic and protein levels offer richer resources for target identification. Notably, the 'expression-without-activation' state of ERBB2 supports the use of ADCs rather than kinase inhibitors—a finding potentially extendable to other similar tumors.
From a drug development perspective, the study supports advancing T-DXd into clinical trials for DSRCT, particularly for ERBB2-low patients. Additionally, CLDN6 and SSTR3/5, as novel targets, provide a theoretical foundation for developing CAR-T and PRRT therapies. Moreover, the application of phosphoproteomics highlights the importance of functional validation, which should be incorporated into routine analytical workflows to distinguish driver from bystander signaling.
Conclusion
This study systematically reveals the multi-omics molecular landscape of DSRCT, significantly improving diagnostic accuracy and providing a robust foundation for personalized therapy through the integration of transcriptomic and phosphoproteomic data. It confirms that even in the absence of kinase activation, high ERBB2 expression can serve as an effective target for T-DXd, challenging the traditional paradigm of targeted therapy reliant on signaling pathway activation. Long-term disease control in two patients validates the potential of ADCs in rare sarcomas. Furthermore, the identification of novel targets such as CLDN6 and SSTR3 lays the groundwork for developing cutting-edge therapies like CAR-T and PRRT. This work underscores the irreplaceable value of multi-omics analysis in rare tumors, driving the transition of DSRCT management from empirical chemotherapy to biomarker-driven precision therapy. In the future, clinical trials based on such molecular classifications are expected to improve outcomes for this lethal disease and build a more comprehensive care system for DSRCT.
